Elite Non-Human Primate (NHP) Monoclonal Antibody Discovery Service

Background Solution Workflow Advantage Related Services FAQ Online Inquiry

Non-Human Primates (NHPs), particularly cynomolgus (Macaca fascicularis) and rhesus (Macaca mulatta) macaques, represent the most predictive animal models due to their profound genetic, physiological, and immunological homology to humans. However, discovering high-quality monoclonal antibodies from these species presents a significant technical challenge. Creative Biolabs stands at the forefront of this challenge, offering a premier Non-Human Primate (NHP) Monoclonal Antibody Discovery Service. With over two decades of expertise, we have engineered a robust, high-efficacy platform that harnesses the power of phage display technology. We specialize in the construction and screening of immune antibody library portfolios from immunized NHPs, delivering high-affinity NHP Monoclonal Antibody candidates with unparalleled specificity and developability for your preclinical research.

Discuss Your Project Today

Advancing Preclinical Research with High-Affinity NHP Monoclonal Antibodies

The demand for high-fidelity preclinical models has never been greater. Rodent models, while useful, often fail to predict the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of human-targeted biologics. Non-Human Primate Monoclonal Antibody candidates and their corresponding NHP models are essential for:

Bridging the Translational Gap: NHPs are frequently the only relevant species that express a drug target ortholog with sufficient sequence identity and binding kinetics to the human counterpart.
Predictive Toxicology & Safety: Assessing potential on-target and off-target toxicities in a human-like immune system is crucial for de-risking a clinical candidate.
Surrogate Antibody Development: An NHP Monoclonal Antibody that cross-reacts with both the human and NHP target (or a surrogate antibody that specifically targets the NHP ortholog) is indispensable for comprehensive PK/PD and efficacy studies.
Mechanism of Action (MoA) Studies: Elucidating a drug's precise biological function in a complex, intact immune system provides invaluable data for clinical trial design.

Despite these needs, traditional antibody discovery methods like hybridoma fusion are notoriously inefficient in NHPs due to low fusion efficiency, clone instability, and limited ethical and logistical sourcing. Creative Biolabs overcomes these hurdles with a superior, state-of-the-art in vitro solution.

Fig. 1 Non-human primates share many similarities with human beings.¹

Our Premier Solution: Phage Display-Based Non-Human Primate (NHP) Monoclonal Antibody Discovery

Creative Biolabs has integrated advanced immunology and molecular engineering to establish a world-class technology platform for phage display-based Non-Human Primate (NHP) Monoclonal Antibody discovery.

Unlike hybridoma technology, which relies on the immortalization of B-cells, our phage display approach directly captures the full, matured antibody repertoire from an immunized NHP. We isolate B-cells from peripheral blood (PBMCs), spleen, or lymph nodes and amplify the variable gene (V-gene) sequences. These sequences are then cloned into our proprietary phagemid vectors, creating a vast immune antibody library that displays the NHP antibody fragments (typically as scFv or Fab) on the surface of bacteriophages.

This immune antibody library for Non-Human Primate (NHP) Monoclonal Antibody discovery becomes a permanent, renewable resource. Through multiple rounds of stringent in vitro selection, known as biopanning, we can isolate highly specific, picomolar-to-nanomolar affinity binders against virtually any target.

The Core Technology: Construction and Screening of NHP Immune Antibody Libraries

Our platform's success is built on meticulous execution at every step. We do not rely on "universal" or "naïve" libraries, which often yield lower-affinity antibodies. Instead, we generate a custom immune antibody library for every project, harnessing the power of in vivo affinity maturation within the NHP.

Why an Immune Library? An immune antibody library is constructed from B-cells of an animal that has been actively immunized against your specific target. This process leverages the NHP's natural immune response, including somatic hypermutation and affinity maturation, to produce B-cells already primed to generate high-affinity antibodies. This results in candidates with superior binding characteristics compared to those isolated from naïve or synthetic repertoires.

The Workflow: From NHP Immunization to Purified Monoclonal Antibody

We offer a comprehensive, end-to-end service, guiding your project from antigen design to the delivery of purified, functional NHP Monoclonal Antibody candidates.

Phase 1: NHP Immunization & B-cell Sourcing

Antigen Strategy: We consult with you on the optimal antigen strategy (e.g., recombinant protein, peptide, whole cells, DNA immunization) to maximize the immune response. We can utilize client-provided antigen or leverage our in-house antigen production services.
Species: We have established protocols for both Cynomolgus and Rhesus macaques, the two most critical species for preclinical studies.
Adjuvant & Protocol: Our expert immunologists employ proprietary immunization strategies and adjuvant formulations to break tolerance (if necessary) and elicit a robust, high-titer polyclonal response.
Material Sourcing: We harvest PBMCs, spleen, or lymph nodes as the source of antigen-specific B-cells.

Phase 2: Immune Antibody Library Construction via Phage Display

RNA Extraction & cDNA Synthesis: High-quality total RNA is extracted from the B-cell population and reverse-transcribed into cDNA.

V-Gene Amplification: Using a highly optimized set of NHP-specific primers, we amplify the complete repertoire of variable heavy (VH) and variable light (VL) chain genes.
Library Cloning: The V-gene repertoires are cloned into our advanced phagemid vectors as either scFv (single-chain variable fragment) or Fab (antigen-binding fragment) formats. This physical linkage of VH and VL is crucial for preserving the original binding pair.
Library Generation: The cloned vectors are transformed into high-efficiency E. coli to generate a primary library. We consistently achieve library sizes exceeding 10^8 - 10^10 individual clones, ensuring comprehensive coverage of the immune response.

Phase 3: Biopanning and Screening of High-Affinity Binders

Biopanning: This is the core selection process. The phage display immune antibody library is subjected to 3-5 rounds of panning against the immobilized target antigen. With each round, non-specific binders are washed away, and high-affinity binders are enriched.
Stringent Selection: We can modulate panning conditions (e.g., antigen concentration, wash stringency, off-target counterscreening) to precisely select for antibodies with desired properties, such as high affinity, specific epitope recognition, or cross-reactivity.
Hit Screening: After panning, individual clones are isolated and screened for target binding using high-throughput methods.

Phase 4: Hit Characterization, Sequencing, and Reformatting

Sequence Analysis: Positive hits are sequenced to identify unique antibody families and confirm diversity.
Affinity Ranking: Promising candidates are expressed as soluble scFv/Fab fragments and subjected to preliminary affinity ranking (e.g., via SPR or BLI).
Reformatting to Full-Length IgG: The V-genes from the best-performing clones are subcloned into mammalian expression vectors containing the appropriate NHP IgG constant regions (e.g., cynomolgus IgG1, IgG4).
Production & QC: The reformatted Non-Human Primate Monoclonal Antibody is produced via transient expression, purified, and subjected to rigorous quality control.

Advantages of Our Phage Display Immune Library Platform

Choosing Creative Biolabs for your NHP Monoclonal Antibody Discovery project provides distinct, tangible advantages over competing technologies.

Unmatched Affinity: By starting with an immune antibody library, we tap into in vivo affinity-matured B-cell populations, resulting in antibodies with picomolar to nanomolar affinity.
Bypassing Hybridoma Limitations: Our platform completely avoids the inefficiencies and instability associated with NHP hybridoma fusion.
Speed and Efficiency: The in vitro nature of phage display screening is significantly faster than traditional clone-picking and stabilization.
Comprehensive Repertoire Access: Phage display captures a far greater diversity of the B-cell repertoire than hybridoma, which is often biased toward dominant, fast-growing clones.
Target Versatility: This platform is effective for all target classes, including challenging proteins like GPCRs, ion channels, and highly conserved antigens.
Renewable Resource: Once constructed, the immune antibody library is a permanent resource that can be re-screened against new targets or variants.

Explore Our Comprehensive Services

While our phage display immune antibody library platform is a powerful engine, we offer a comprehensive suite of discovery technologies to ensure we always use the right tool for the job. Our Monoclonal Antibody Generation from Various Immunized Antibody Libraries Services:

Do not let the challenges of preclinical model validation slow down your therapeutic pipeline. Leverage the expertise of Creative Biolabs and our state-of-the-art Non-Human Primate (NHP) Monoclonal Antibody Discovery Service. Contact our team of experts to discuss your project and receive a customized proposal.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: What Non-Human Primate (NHP) species do you support?

A: We primarily support the two most common species used in preclinical research: cynomolgus macaques (Macaca fascicularis) and rhesus macaques (Macaca mulatta).

Q: Why should I choose your phage display immune library service over traditional NHP hybridoma?

A: Efficiency and stability. NHP hybridoma development is extremely challenging, with very low fusion efficiency and a high rate of clone instability, often resulting in project failure. Our phage display-based Non-Human Primate (NHP) Monoclonal Antibody discovery platform is far more robust, faster, and accesses a much larger portion of the immune repertoire, leading to a higher probability of success and higher-affinity candidates.

Q: What is the advantage of an "immune" library over a "naïve" library?

A: Affinity. An immune antibody library is built from an NHP that has been immunized against your target. This leverages in vivo affinity maturation, meaning the B-cells are already "pre-selected" and optimized to produce high-affinity antibodies. Naïve libraries are built from non-immunized donors and typically yield lower-affinity (micromolar range) antibodies that require extensive downstream affinity maturation.

Q: What kind of antigen do I need to provide?

A: We are highly flexible. We can work with recombinant proteins (tagged or untagged), peptides, DNA, or even whole cells expressing the target. Our team can also synthesize or express the antigen for you as part of the service package.

Reference

Zhang, Sihui, et al. "Non‐human primate models of Parkinson's disease: Decoding pathogenesis and advancing therapies." Brain‐X 3.2 (2025): e70032. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1002/brx2.70032

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.